APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Ovarian Cancer Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Metastatic Ovarian Cancer Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchMetastatic Ovarian Cancer Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Ovarian Cancer Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Metastatic Ovarian Cancer Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Ovarian Cancer Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Ovarian Cancer Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Metastatic Ovarian Cancer Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Metastatic Ovarian Cancer Drug include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc. and Sumitomo Dainippon Pharma Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metastatic Ovarian Cancer Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metastatic Ovarian Cancer Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metastatic Ovarian Cancer Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metastatic Ovarian Cancer Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Metastatic Ovarian Cancer Drug Segment by Company

Adgero Biopharmaceuticals Inc

Cellceutix Corporation

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Eisai Co., Ltd.

Metastatic Ovarian Cancer Drug Segment by Type

E-749

Crizotinib

LV-305

G-305

CMB-305

Others

Metastatic Ovarian Cancer Drug Segment by Application

Clinic

Hospital

Others

Metastatic Ovarian Cancer Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Ovarian Cancer Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Ovarian Cancer Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Ovarian Cancer Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metastatic Ovarian Cancer Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Metastatic Ovarian Cancer Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Metastatic Ovarian Cancer Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Metastatic Ovarian Cancer Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Metastatic Ovarian Cancer Drug Industry Trends Table 2. Metastatic Ovarian Cancer Drug Industry Drivers Table 3. Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges Table 4. Metastatic Ovarian Cancer Drug Industry Restraints Table 5. Global Metastatic Ovarian Cancer Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Metastatic Ovarian Cancer Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Metastatic Ovarian Cancer Drug Sales Market Share by Manufacturers Table 9. Global Metastatic Ovarian Cancer Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Metastatic Ovarian Cancer Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Metastatic Ovarian Cancer Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Metastatic Ovarian Cancer Drug Manufacturers, Product Type & Application Table 13. Global Metastatic Ovarian Cancer Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Metastatic Ovarian Cancer Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of E-749 Table 17. Major Manufacturers of Crizotinib Table 18. Major Manufacturers of LV-305 Table 19. Major Manufacturers of G-305 Table 20. Major Manufacturers of CMB-305 Table 21. Major Manufacturers of Others Table 22. Global Metastatic Ovarian Cancer Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2026) Table 26. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2027-2032) Table 27. Global Metastatic Ovarian Cancer Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2026) Table 31. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Others Table 35. Global Metastatic Ovarian Cancer Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2026) Table 39. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2027-2032) Table 40. Global Metastatic Ovarian Cancer Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2026) Table 44. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2027-2032) Table 45. Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2021-2026) Table 48. Global Metastatic Ovarian Cancer Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Metastatic Ovarian Cancer Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Metastatic Ovarian Cancer Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Metastatic Ovarian Cancer Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Metastatic Ovarian Cancer Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2021-2026) Table 66. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2027-2032) Table 67. Adgero Biopharmaceuticals Inc Company Information Table 68. Adgero Biopharmaceuticals Inc Business Overview Table 69. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 71. Adgero Biopharmaceuticals Inc Recent Development Table 72. Cellceutix Corporation Company Information Table 73. Cellceutix Corporation Business Overview Table 74. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio Table 76. Cellceutix Corporation Recent Development Table 77. F. Hoffmann-La Roche Ltd. Company Information Table 78. F. Hoffmann-La Roche Ltd. Business Overview Table 79. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 81. F. Hoffmann-La Roche Ltd. Recent Development Table 82. Immune Design Corp. Company Information Table 83. Immune Design Corp. Business Overview Table 84. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio Table 86. Immune Design Corp. Recent Development Table 87. Millennium Pharmaceuticals Inc Company Information Table 88. Millennium Pharmaceuticals Inc Business Overview Table 89. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 91. Millennium Pharmaceuticals Inc Recent Development Table 92. MolMed S.p.A. Company Information Table 93. MolMed S.p.A. Business Overview Table 94. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio Table 96. MolMed S.p.A. Recent Development Table 97. Natco Pharma Limited Company Information Table 98. Natco Pharma Limited Business Overview Table 99. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio Table 101. Natco Pharma Limited Recent Development Table 102. Northwest Biotherapeutics, Inc. Company Information Table 103. Northwest Biotherapeutics, Inc. Business Overview Table 104. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 106. Northwest Biotherapeutics, Inc. Recent Development Table 107. Sumitomo Dainippon Pharma Co., Ltd. Company Information Table 108. Sumitomo Dainippon Pharma Co., Ltd. Business Overview Table 109. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 111. Sumitomo Dainippon Pharma Co., Ltd. Recent Development Table 112. VG Life Sciences, Inc. Company Information Table 113. VG Life Sciences, Inc. Business Overview Table 114. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 116. VG Life Sciences, Inc. Recent Development Table 117. Pfizer Inc. Company Information Table 118. Pfizer Inc. Business Overview Table 119. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 121. Pfizer Inc. Recent Development Table 122. Richter Gedeon Nyrt. Company Information Table 123. Richter Gedeon Nyrt. Business Overview Table 124. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio Table 126. Richter Gedeon Nyrt. Recent Development Table 127. Eisai Co., Ltd. Company Information Table 128. Eisai Co., Ltd. Business Overview Table 129. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 131. Eisai Co., Ltd. Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Metastatic Ovarian Cancer Drug Distributors List Table 135. Metastatic Ovarian Cancer Drug Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Metastatic Ovarian Cancer Drug Product Image Figure 2. Global Metastatic Ovarian Cancer Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Ovarian Cancer Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Metastatic Ovarian Cancer Drug Sales (2021-2032) & (K Units) Figure 5. Global Metastatic Ovarian Cancer Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Metastatic Ovarian Cancer Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. E-749 Image Figure 9. Crizotinib Image Figure 10. LV-305 Image Figure 11. G-305 Image Figure 12. CMB-305 Image Figure 13. Others Image Figure 14. Global Metastatic Ovarian Cancer Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Metastatic Ovarian Cancer Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2032) Figure 17. Global Metastatic Ovarian Cancer Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Metastatic Ovarian Cancer Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Metastatic Ovarian Cancer Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Metastatic Ovarian Cancer Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2032) Figure 26. Global Metastatic Ovarian Cancer Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Metastatic Ovarian Cancer Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Metastatic Ovarian Cancer Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Metastatic Ovarian Cancer Drug Sales Market Share by Country (2021-2032) Figure 43. China Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Metastatic Ovarian Cancer Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Metastatic Ovarian Cancer Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Metastatic Ovarian Cancer Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Metastatic Ovarian Cancer Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • E-749
  • Crizotinib
  • LV-305
  • G-305
  • CMB-305
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Adgero Biopharmaceuticals Inc
  • Cellceutix Corporation
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals Inc
  • MolMed S.p.A.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • VG Life Sciences, Inc.
  • Pfizer Inc.
  • Richter Gedeon Nyrt.
  • Eisai Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Metastatic Ovarian Cancer Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Metastatic Ovarian Cancer Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Metastatic Ovarian Cancer Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Metastatic Ovarian Cancer Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Metastatic Ovarian Cancer Drug Market Dynamics
  1. 2.1 Metastatic Ovarian Cancer Drug Industry Trends
  2. 2.2 Metastatic Ovarian Cancer Drug Industry Drivers
  3. 2.3 Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Ovarian Cancer Drug Industry Restraints
3 Metastatic Ovarian Cancer Drug Market by Manufacturers
  1. 3.1 Global Metastatic Ovarian Cancer Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Metastatic Ovarian Cancer Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Metastatic Ovarian Cancer Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Metastatic Ovarian Cancer Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Metastatic Ovarian Cancer Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Metastatic Ovarian Cancer Drug Manufacturers, Product Type & Application
  7. 3.7 Global Metastatic Ovarian Cancer Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Metastatic Ovarian Cancer Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Metastatic Ovarian Cancer Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Metastatic Ovarian Cancer Drug Tier 1, Tier 2, and Tier 3
4 Metastatic Ovarian Cancer Drug Market by Type
  1. 4.1 Metastatic Ovarian Cancer Drug Type Introduction
  2. 4.1.1 E-749
  3. 4.1.2 Crizotinib
  4. 4.1.3 LV-305
  5. 4.1.4 G-305
  6. 4.1.5 CMB-305
  7. 4.1.6 Others
  8. 4.2 Global Metastatic Ovarian Cancer Drug Sales by Type
  9. 4.2.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Metastatic Ovarian Cancer Drug Revenue by Type
  13. 4.3.1 Global Metastatic Ovarian Cancer Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2032)
5 Metastatic Ovarian Cancer Drug Market by Application
  1. 5.1 Metastatic Ovarian Cancer Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Metastatic Ovarian Cancer Drug Sales by Application
  6. 5.2.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Metastatic Ovarian Cancer Drug Revenue by Application
  10. 5.3.1 Global Metastatic Ovarian Cancer Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2032)
6 Global Metastatic Ovarian Cancer Drug Sales by Region
  1. 6.1 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Metastatic Ovarian Cancer Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Metastatic Ovarian Cancer Drug Revenue by Region
  1. 7.1 Global Metastatic Ovarian Cancer Drug Revenue by Region
  2. 7.1.1 Global Metastatic Ovarian Cancer Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Metastatic Ovarian Cancer Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Metastatic Ovarian Cancer Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Metastatic Ovarian Cancer Drug Revenue (2021-2032)
  8. 7.2.2 North America Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Metastatic Ovarian Cancer Drug Revenue (2021-2032)
  11. 7.3.2 Europe Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Metastatic Ovarian Cancer Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Metastatic Ovarian Cancer Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Adgero Biopharmaceuticals Inc
  2. 8.1.1 Adgero Biopharmaceuticals Inc Company Information
  3. 8.1.2 Adgero Biopharmaceuticals Inc Business Overview
  4. 8.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  6. 8.1.5 Adgero Biopharmaceuticals Inc Recent Developments
  7. 8.2 Cellceutix Corporation
  8. 8.2.1 Cellceutix Corporation Company Information
  9. 8.2.2 Cellceutix Corporation Business Overview
  10. 8.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio
  12. 8.2.5 Cellceutix Corporation Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Immune Design Corp.
  20. 8.4.1 Immune Design Corp. Company Information
  21. 8.4.2 Immune Design Corp. Business Overview
  22. 8.4.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio
  24. 8.4.5 Immune Design Corp. Recent Developments
  25. 8.5 Millennium Pharmaceuticals Inc
  26. 8.5.1 Millennium Pharmaceuticals Inc Company Information
  27. 8.5.2 Millennium Pharmaceuticals Inc Business Overview
  28. 8.5.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  30. 8.5.5 Millennium Pharmaceuticals Inc Recent Developments
  31. 8.6 MolMed S.p.A.
  32. 8.6.1 MolMed S.p.A. Company Information
  33. 8.6.2 MolMed S.p.A. Business Overview
  34. 8.6.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio
  36. 8.6.5 MolMed S.p.A. Recent Developments
  37. 8.7 Natco Pharma Limited
  38. 8.7.1 Natco Pharma Limited Company Information
  39. 8.7.2 Natco Pharma Limited Business Overview
  40. 8.7.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio
  42. 8.7.5 Natco Pharma Limited Recent Developments
  43. 8.8 Northwest Biotherapeutics, Inc.
  44. 8.8.1 Northwest Biotherapeutics, Inc. Company Information
  45. 8.8.2 Northwest Biotherapeutics, Inc. Business Overview
  46. 8.8.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  48. 8.8.5 Northwest Biotherapeutics, Inc. Recent Developments
  49. 8.9 Sumitomo Dainippon Pharma Co., Ltd.
  50. 8.9.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
  51. 8.9.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
  52. 8.9.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
  55. 8.10 VG Life Sciences, Inc.
  56. 8.10.1 VG Life Sciences, Inc. Company Information
  57. 8.10.2 VG Life Sciences, Inc. Business Overview
  58. 8.10.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  60. 8.10.5 VG Life Sciences, Inc. Recent Developments
  61. 8.11 Pfizer Inc.
  62. 8.11.1 Pfizer Inc. Company Information
  63. 8.11.2 Pfizer Inc. Business Overview
  64. 8.11.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  66. 8.11.5 Pfizer Inc. Recent Developments
  67. 8.12 Richter Gedeon Nyrt.
  68. 8.12.1 Richter Gedeon Nyrt. Company Information
  69. 8.12.2 Richter Gedeon Nyrt. Business Overview
  70. 8.12.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio
  72. 8.12.5 Richter Gedeon Nyrt. Recent Developments
  73. 8.13 Eisai Co., Ltd.
  74. 8.13.1 Eisai Co., Ltd. Company Information
  75. 8.13.2 Eisai Co., Ltd. Business Overview
  76. 8.13.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  78. 8.13.5 Eisai Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metastatic Ovarian Cancer Drug Value Chain Analysis
  2. 9.1.1 Metastatic Ovarian Cancer Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metastatic Ovarian Cancer Drug Production Mode & Process
  6. 9.2 Metastatic Ovarian Cancer Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metastatic Ovarian Cancer Drug Distributors
  9. 9.2.3 Metastatic Ovarian Cancer Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst